



CORPORATE PRESENTATION

NASDAQ COMMON: XOMA

NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO

APRIL 2024

THE ROYALTY
AGGREGATOR
FOR BIOTECH
COMPANIES

DISCLAIMERS



Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for significant financial contribution, the ability of our partners and their licensees to successfully develop their pipeline programs, the productivity of acquired assets, our revenue and cashflow forecasts, upcoming internal milestones and value catalysts, our future cash needs, our strategy for value creation, and other statements that relate to future periods. These statements are not guarantees of future performance and undue reliance should not be placed on them. They are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.

Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filings on Form 10-K and Form 10-Q. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statements represent XOMA's views

only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by law.

NOTE: All references to "portfolio" in this presentation are to milestone and/or royalty rights associated with a basket of drug products in development. All references to "assets" in this presentation are to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates contained herein refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

XOMA - WHAT WE DO



The Biotech Royalty Aggregator

BUILDING THE XOMA BUSINESS



Scalable

BUSINESS
MODEL

\$95M+
since 2017

MILESTONES

+
New
Deals

60+
assets

PIPELINE



PHASE 3 /
REGISTRATION



COMMERCIAL
ROYALTIES

XOMA BUSINESS MODEL: THE COMPOUNDING EFFECT

↑ CASH RECEIPTS


— LOW EXPENSES

÷ LOW SHARE COUNT

HIGH EPS

SIGNIFICANT
SHARE PRICE
APPRECIATION

Path to Sustained Profitability



XOMA IS DIFFERENTIATED IN THE ROYALTY SPACE

Capital per transaction

\$200M+

\$100M -
\$200M

\$25M -
\$100M

<\$25M

Royalty Pharma

DRI Healthcare Trust

Ligand

HCRx

FOCUSED ON
EARLY-to-MID STAGE
CLINICAL ASSETS

XOMA
ROYALTY

PRECLINICAL

PHASE 1


PHASE 2

PHASE 3

APPROVAL

COMMERCIAL

XOMA'S BUSINESS MODEL DIFFERENTIATION SHOULD ENHANCE VALUE CREATION



Visibility into future
royalty portfolio
differentiates XOMA
from majority of
royalty competitors

XOMA'S TIME IS NOW...

LIFE SCIENCES MARKETS ARE CHALLENGED...

EQUITY

↓ Volume



DEBT

↑ Cost



PARTNER

↓ Volume



M&A

↓ Volume



...CREATING OPPORTUNITY

**ROYALTY
MONETIZATION**


↓ Equity Dilution

Unlock Latent Value

↑ Capital Efficiency

OPPORTUNITIES ABOUND FOR ROYALTY MONETIZATION

LIFE SCIENCES INDUSTRY LICENSING DEALS ANNUALLY
2014 - 2022




License transactions consist of:


- Upfront payment
- Milestone payments
- Royalty obligations

BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION

2 Royalty Monetization



1 License Agreement



XOMA'S IDEAL ROYALTY ASSET



HIGH ROYALTY POTENTIAL

High unmet need or clear clinical benefit over alternatives



LONG DURATION OF MARKET EXCLUSIVITY

Patent expiration or regulatory exclusivity



ESTABLISHED DEVELOPER / MARKETER


Assets partnered with reputable pharma / biopharma






MID TO EARLY-STAGE CLINICAL ASSETS

Therapeutic area, modality agnostic


KEY ASSETS IN XOMA PORTFOLIO

 = 2023 + 2024 Transactions


ASSET	PARTNER	INDICATION	STAGE	CONSENSUS PEAK SALES ¹	ROYALTY %
VABYSMO®	Roche	Wet AMD / DME	Commercial	\$5.1B	0.50%
 IXINITY®	Medexus	Hemophilia B	Commercial	\$57M	5%
 DSUVIA®	Alora Pharmaceuticals	Acute pain in supervised medical setting	Commercial	NA	15 – 75%
Tovorafenib	Day One	pLGG	Registration	\$1.2B	Mid-single
 Arimoclomol	Zevra	Niemann-Pick Type C	Registration	\$621M	Mid-single
Cetrelimab	JNJ	Bladder Cancer	Phase 3	\$2.1B	0.75%
RZ358	Rezolute	CHI	Phase 3	\$600M	High single / mid-teens
Rilvegostomig	AZN / Compugen	Solid Tumor(s)	Phase 3	NA	undisclosed
Ficlatuzumab	AVEO	HNSCC	Phase 3	NA	Low single digit
Mezagitamab	Takeda	ITP	Phase 3	\$1.0B	4%
Vidutolimod	Regeneron	CSCC / MCC / BCC	Phase 2	NA	High single / double digit

1. Peak sales per Wall Street Research, Bloomberg

XOMA PORTFOLIO CONSTRUCTION



RISK-MITIGATED



DIVERSIFIED

Indication
Mechanism
Modality



WELL-STRUCTURED



THE POWER OF THE XOMA MODEL

A Single Transaction¹ Can Deliver Significant Value for Shareholders

Dec 2023

ROYALTY-BACKED LOAN



**XOMA Raises up to \$140 Million in
Non-Dilutive, Non-Recourse Financing from
Funds Managed by Blue Owl Capital
Backed by VABYSMO[®] Royalties**

\$140M³

Low Cost of Capital

Tax Efficient

Preserve NOLs

Interest Expense ↓

Taxable Income

Maintain Ownership & Upside

Oct 2021^{1,2}

ACQUISITION

\$14M

USE OF PROCEEDS: DELIVER ADDITIONAL SHAREHOLDER VALUE

**Share
Repurchase**





**Royalty
Acquisitions**

1. Acquired economics agreement from Affitech SA 2. Up to an additional \$12M in sales-based milestones may be paid to Affitech SA 3. \$130M initial draw; additional \$10M if VABYSMO[®] royalties exceed certain threshold



TOVORAFENIB + VOSAROXIN TRANSACTION:

\$13.5M upfront to Viracta Therapeutics



	tovorafenib	vosaroxin
Indication	Pediatric low-grade glioma	Myelodysplastic syndromes + AML
Milestone Potential	\$54M	\$57M
Royalty Rate	Mid-single digits	High single digits
Clinical Stage	PDUFA April 30, 2024 ¹ NDA filed Oct 2023	Phase 2
Partner	 Day One BIOPHARMACEUTICALS	 Denovo Biopharma

1. <https://ir.dayonebio.com/news-releases/news-release-details/day-one-announces-fda-acceptance-nda-and-priority-review>

ARIMOCLOMOL + ALDOXORUBICIN TRANSACTION:

\$6M to LadRx¹

Arimoclomol will be a first-in-class therapy if approved by regulatory authorities for NPC

	arimoclomol	aldoxorubicin
Indication	Niemann-Pick Type C	Pancreatic Cancer
Milestone Potential	\$52.6M	\$343M
Royalty Rate	Mid-single digits	Mid-single to mid-teens
Clinical Stage	PDUFA September 21, 2024 ² NDA Resubmitted 12/27/2023	Phase 2 (Aldox+Anktiva+PD-L1 t-hANK)
Partner		


1. \$5M upfront. \$1M milestone paid to LadRx on FDA's acceptance of NDA resubmission. Up to an additional \$5M in milestones may be paid to LadRx
2. <https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-provides-fda-update-pdufa-action-date>



IXINITY[®] TRANSACTION:

\$9.6M upfront to Aptevo
Royalties through 1Q2035



	IXINITY [®]
Indication	Hemophilia B
Milestone Potential	undisclosed
Royalty Rate	5%
Clinical Stage	FDA approved & commercialized; sBLA approved in March 2024 for pediatric use <12 yo
Partner	

DSUVIA® TRANSACTION:

\$8M upfront to Talphera

DSUVIA®
(sufentanil sublingual tablet)

Indication

For use in adults in certified medically supervised healthcare settings to treat acute pain

Use Case

Department of Defense –
Deployed Troops Sets, Kits, Outfits (SKOs)

Milestone Potential

\$116.5M
shared with Talphera

Royalty Rate

37.5% - 75% of DoD Contracts
15% of commercial sales

Clinical Stage

FDA approved & commercialized

Partner

ALORA
pharmaceuticals



KEY PORTFOLIO EVENTS 2024 INTO 2025



Commercial
Indication Expansion



NDA Approval*
tovorafenib



FPFD in P3**
RZ358



P3 Launch
mezagitamab



**ADDITIONAL
BUSINESS
DEVELOPMENT**



Commercial
RELAUNCH



Phase 2b data
PD-1/TIGIT
HCC, NSCLC



Phase 2 data
CD38
ITP, IgA
Neuropathy

REGENERON

Phase 2 data
TLR9
Melanoma(s)



NDA Approval***
arimoclomol

BLUE OWL FINANCING – UP TO \$140M



TERMS

\$130M at close

9.875% interest

**Secured only by
VABYSMO royalties**



STOCKHOLDER BENEFIT

**Acquire assets for
cash flow growth**

Stock repurchases

**XOMA retains
long-term value of
VABYSMO**



WELL-STRUCTURED

**Non-dilutive, non-
recourse capital**

Scaled \$14M acquisition

**Strategic partnership
with Blue Owl**



KINNATE TRANSACTION:

~\$9.5M cash

added to XOMA's balance sheet for additional capital deployment & potential royalties on pipeline

Cash Amount
(per share)

\$2.5879

Contingent Value Right
(CVR)


85%
of net proceeds

from out license or
sale of Kinnate
programs completed
within 1 year of closing

100%
of net proceeds

from Kinnate's sale of
exarafenib and pan-
RAF inhibitor program
to Pierre Fabre

FINANCIAL HIGHLIGHTS



>\$95M

in milestones
since 2017

>\$1B

in potential
milestones

3 assets

generating
royalty receipts

Potential of **2**

additional royalty
streams in 2024

Stable Expense Base

XOMA'S STOCK REPURCHASE PROGRAM

Up to
\$50 Million

through January 2, 2027

DRIVING SHAREHOLDER VALUE

THREE PUBLICLY TRADED OFFERINGS TO MEET THE NEEDS OF SPECIFIC INVESTORS

XOMA
Common Stock

XOMAP

Series A Cumulative Perpetual Preferred Stock
\$25.00 par value

8.625% dividend paid quarterly

XOMAO

Series B Cumulative Perpetual Preferred Stock
\$25.00 par value

8.375% dividend paid quarterly

WHO WE ARE

- **Leadership**
 - Owen Hughes, Chief Executive Officer
 - Brad Sitko, Chief Investment Officer
 - Tom Burns, Chief Financial Officer
- **Business Development Team**
- **Legal Team**
- **Finance Team**
- **Consultants**
 - Deal Sourcing
 - Scientific
 - Medical

Board of Directors

- **Jack Wyszomierski, Chairman**
CFO of VWR International (retired)
- **Heather L. Franklin**
Executive Chair of Blaze Bioscience
- **Natasha Hernday**
CBO of Seagen (former)
- **Owen Hughes**
CEO of XOMA
- **Barbara Kosacz**
COO and GC of Kronos Bio (former)
- **Joe Limber**
CEO of Secura Bio
- **Matthew Perry**
President at BVF Partners (former)

XOMA'S TIME IS NOW

INFLECTION
POINT
FORTHCOMING

EFFICIENT
BUSINESS MODEL

COMPETITIVE
DIFFERENTIATION

ROYALTIES TO
DRIVE
SHAREHOLDER
RETURNS



Enabling Today's Science to Be
Tomorrow's Cures



CORPORATE PRESENTATION

NASDAQ COMMON: XOMA

NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO

APRIL 2024

THE ROYALTY
AGGREGATOR
FOR BIOTECH
COMPANIES